Page title

Advisory: Sublingual and Transmucosal Buprenorphine for Opioid Use Disorder: Review and Update

Main page content

This advisory summarizes data on the use of sublingual and transmucosal buprenorphine as part of medication-assisted treatment (MAT) for opioid use disorder.

Authoring Agency

Substance Abuse and Mental Health Services Administration (SAMHSA)

View Resource